Magnetic Resonance Spectroscopic and Diffusion Tensor Imaging of Adolescents With Autism Spectrum Disorders
The primary objective of this study is to conduct magnetic resonance spectroscopic (MRS) and imaging (MRI) scans to assess the structural and neurochemical profile of the brain in 20 children and adolescents, 6-17 years old with Autism Spectrum Disorder (ASD). For comparison, MRS and MRI will also be obtained from 10 healthy control subjects, matched to the 20 subjects with ASD in age, sex, dexterity, and IQ. All eligible subjects will be administered a detailed assessment battery consisting of cognitive assessments (neuropsychological battery including subsets of the DANVA2 and the CANTAB) and measures of psychosocial functioning (SAICA and M-FES). The study includes 1-3 visits for the screening period at Massachusetts General Hospital (approximately 4 hours of assessments) and one scanning visit at McLean Hospital (approximately 1.5 hours).
The investigators hypothesize that youth with ASD versus controls will exhibit increased glutamate concentrations, reflecting glutamatergic overactivity, and increased Cho concentrations, suggesting neuronal abnormality. Furthermore, the investigators hypothesize that compared to neurotypical controls, the structural integrity of white mater tracts will be disrupted in ASD.
Autism Spectrum Disorders
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Magnetic Resonance Spectroscopic and Diffusion Tensor Imaging of Adolescents With Autism Spectrum Disorders|
- Structural and neurochemical profiles of adolescents with ASD [ Time Frame: scanning visit (1.5 hours) ] [ Designated as safety issue: No ]Concentrations of various neurochemicals, including glutamate, will be examined in addition to the structural integrity of white matter tracts. These results will be compared to results from control subjects.
|Study Start Date:||April 2010|
|Estimated Study Completion Date:||April 2015|
|Estimated Primary Completion Date:||April 2015 (Final data collection date for primary outcome measure)|
|Autism Spectrum Disorder (ASD)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01361503
|Contact: Stephannie Furtak, BAemail@example.com|
|Contact: Leah Feinberg, BSfirstname.lastname@example.org|
|United States, Massachusetts|
|Belmont, Massachusetts, United States, 02478|
|Contact: Scott Lukas 617-855-2767|
|Massachusetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02114|
|Contact: Stephannie Furtak, BA 617-724-2344 email@example.com|
|Contact: Leah Feinberg, BS 617-726-4651 firstname.lastname@example.org|
|Principal Investigator:||Gagan Joshi, MD||Massachusetts General Hospital|